Headlands Technologies LLC Sells 38,452 Shares of Agios Pharmaceuticals, Inc. $AGIO

Headlands Technologies LLC lowered its stake in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 64.9% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 20,805 shares of the biopharmaceutical company’s stock after selling 38,452 shares during the period. Headlands Technologies LLC’s holdings in Agios Pharmaceuticals were worth $772,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of the stock. Sei Investments Co. grew its holdings in Agios Pharmaceuticals by 342.8% during the first quarter. Sei Investments Co. now owns 63,550 shares of the biopharmaceutical company’s stock valued at $2,150,000 after purchasing an additional 49,198 shares during the period. SCS Capital Management LLC bought a new stake in shares of Agios Pharmaceuticals in the second quarter valued at $22,743,000. State of New Jersey Common Pension Fund D bought a new stake in shares of Agios Pharmaceuticals in the fourth quarter valued at $1,291,000. GW&K Investment Management LLC lifted its position in shares of Agios Pharmaceuticals by 41.5% during the 4th quarter. GW&K Investment Management LLC now owns 1,207,301 shares of the biopharmaceutical company’s stock valued at $32,863,000 after buying an additional 354,359 shares during the last quarter. Finally, Seven Fleet Capital Management LP purchased a new position in shares of Agios Pharmaceuticals during the 4th quarter valued at $864,000.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on AGIO shares. Royal Bank Of Canada increased their price target on Agios Pharmaceuticals from $28.00 to $32.00 and gave the stock a “sector perform” rating in a research note on Tuesday, July 7th. Truist Financial dropped their price objective on shares of Agios Pharmaceuticals from $41.00 to $39.00 and set a “buy” rating on the stock in a report on Friday, July 31st. JPMorgan Chase & Co. increased their target price on shares of Agios Pharmaceuticals from $31.00 to $34.00 and gave the stock a “neutral” rating in a research report on Friday, August 7th. Weiss Ratings reiterated a “sell (d)” rating on shares of Agios Pharmaceuticals in a research note on Wednesday, June 24th. Finally, TD Cowen raised shares of Agios Pharmaceuticals to a “strong-buy” rating in a research report on Monday, August 24th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $41.25.

Insiders Place Their Bets

In other Agios Pharmaceuticals news, insider Sarah Gheuens sold 30,000 shares of Agios Pharmaceuticals stock in a transaction dated Tuesday, August 4th. The stock was sold at an average price of $30.48, for a total transaction of $914,400.00. Following the completion of the transaction, the insider owned 54,645 shares of the company’s stock, valued at $1,665,579.60. The trade was a 35.44% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 5.40% of the stock is owned by insiders.

Agios Pharmaceuticals Price Performance

Agios Pharmaceuticals stock opened at $34.21 on Wednesday. Agios Pharmaceuticals, Inc. has a one year low of $22.24 and a one year high of $46.00. The business has a fifty day moving average price of $35.84 and a 200-day moving average price of $31.75. The firm has a market capitalization of $2.04 billion, a P/E ratio of -4.88 and a beta of 0.60.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported ($1.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.65) by ($0.04). The company had revenue of $44.75 million for the quarter, compared to the consensus estimate of $26.39 million. Agios Pharmaceuticals had a negative net margin of 418.24% and a negative return on equity of 35.67%. Sell-side analysts expect that Agios Pharmaceuticals, Inc. will post -5.82 earnings per share for the current fiscal year.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.